RE: RNS.................Issue of Equity24 Jul 2018 08:06
From last weeks Ichor RNS...................................
As expected, and in line with the Company's commercialisation plans, an option fee will be payable (within 30 days of exercise) to Ichor, with further milestone payments due from the start of future Phase 3 clinical trials. The Company has also granted an extension of the period for exercise of the Tranche 2 share options (3,184,620 ordinary shares) issued as part payment for the licence option, which will be immediately exercised by, subscribed for and allotted to Ichor, as part of the Company's exercise of the commercial licence option.  Ichor has agreed to hold these Tranche 2 shares for a period of at least two years from their date of issue.
Todays issue of equity................................""".Scancell Holdings plc, ("Scancell" or the "Company") the developer of novel immunotherapies for the treatment of cancer, confirms that further to the announcement made on 18 July 2018 regarding the exercise of share options, the Company has issued, 3,184,620 new ordinary shares ("New Shares").
Tidy enough!!!